FLUDARA

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

FLUDARABINE PHOSPHATE 50 MG/VIAL

Commercializzato da:

SANOFI - AVENTIS ISRAEL LTD

Codice ATC:

L01BB05

Forma farmaceutica:

POWDER FOR SOLUTION FOR INJ/INF

Via di somministrazione:

I.V

Prodotto da:

GENZYME EUROPE B.V., NETHERLANDS

Gruppo terapeutico:

FLUDARABINE

Indicazioni terapeutiche:

Palliative treatment of patients with CLL refractory to other therapy. Treatment of less malignant Non-Hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. Fludara is indicated for the initial treatment of patients with B- cell chronic lymphocytic leukaemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves.

Data dell'autorizzazione:

2009-02-01